HC Wainwright set a $3.00 price objective on Arch Therapeutics (OTCMKTS:ARTH) in a research note released on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research upgraded shares of Arch Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Arch Therapeutics currently has a consensus rating of Buy and an average price target of $1.75.

ARTH stock opened at $0.43 on Monday. Arch Therapeutics has a 12 month low of $0.25 and a 12 month high of $0.85.

About Arch Therapeutics

Arch Therapeutics, Inc, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.

Featured Article: Market Capitalization – What it Means for Investors

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.